GRAND PHARMA (00512): Self-Developed Global Innovative Radiopharmaceutical GPN01530 Approved for Clinical Trials in the U.S.

Stock News12-17 18:10

GRAND PHARMA (00512) announced that its self-developed global innovative radiopharmaceutical conjugate (RDC) GPN01530 has recently received formal approval from the U.S. Food and Drug Administration (FDA) to commence Phase I/II clinical studies for the diagnosis of solid tumors. This marks another significant step in the company's global expansion in the field of nuclear medicine for oncology diagnostics and treatment.

As the company's first self-developed RDC product to receive FDA approval for clinical trials, the successful clearance of GPN01530's clinical study provides an important model for the international development of GRAND PHARMA's nuclear medicine pipeline. It represents a key milestone in the company's global R&D and regulatory progress for oncology diagnostics and treatment, demonstrating its comprehensive capabilities in cutting-edge nuclear medicine technology platforms, international clinical development, and regulatory submissions.

Leveraging its "dual submission in China and the U.S." strategy for global registration, GRAND PHARMA will continue advancing the worldwide R&D and regulatory efforts for GPN01530. Building on this foundation, the company plans to further deepen its globalization strategy in this sector, actively promoting international clinical research and regulatory filings for more self-developed innovative nuclear medicine products. This initiative aims to enhance GRAND PHARMA's core competitiveness and global influence in nuclear medicine for oncology diagnostics and treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195721045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195721045","market":"us","top_or_hot":-1,"title":"GRAND PHARMA (00512): Self-Developed Global Innovative Radiopharmaceutical GPN01530 Approved for Clinical Trials in the U.S.","media":"Stock News","content":"<p>GRAND PHARMA (00512) announced that its self-developed global innovative radiopharmaceutical conjugate (RDC) GPN01530 has recently received formal approval from the U.S. Food and Drug Administration (FDA) to commence Phase I/II clinical studies for the diagnosis of solid tumors. This marks another significant step in the company's global expansion in the field of nuclear medicine for oncology diagnostics and treatment.</p>\n<p>As the company's first self-developed RDC product to receive FDA approval for clinical trials, the successful clearance of GPN01530's clinical study provides an important model for the international development of GRAND PHARMA's nuclear medicine pipeline. It represents a key milestone in the company's global R&D and regulatory progress for oncology diagnostics and treatment, demonstrating its comprehensive capabilities in cutting-edge nuclear medicine technology platforms, international clinical development, and regulatory submissions.</p>\n<p>Leveraging its \"dual submission in China and the U.S.\" strategy for global registration, GRAND PHARMA will continue advancing the worldwide R&D and regulatory efforts for GPN01530. Building on this foundation, the company plans to further deepen its globalization strategy in this sector, actively promoting international clinical research and regulatory filings for more self-developed innovative nuclear medicine products. This initiative aims to enhance GRAND PHARMA's core competitiveness and global influence in nuclear medicine for oncology diagnostics and treatment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GRAND PHARMA (00512): Self-Developed Global Innovative Radiopharmaceutical GPN01530 Approved for Clinical Trials in the U.S.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGRAND PHARMA (00512): Self-Developed Global Innovative Radiopharmaceutical GPN01530 Approved for Clinical Trials in the U.S.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-17 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GRAND PHARMA (00512) announced that its self-developed global innovative radiopharmaceutical conjugate (RDC) GPN01530 has recently received formal approval from the U.S. Food and Drug Administration (FDA) to commence Phase I/II clinical studies for the diagnosis of solid tumors. This marks another significant step in the company's global expansion in the field of nuclear medicine for oncology diagnostics and treatment.</p>\n<p>As the company's first self-developed RDC product to receive FDA approval for clinical trials, the successful clearance of GPN01530's clinical study provides an important model for the international development of GRAND PHARMA's nuclear medicine pipeline. It represents a key milestone in the company's global R&D and regulatory progress for oncology diagnostics and treatment, demonstrating its comprehensive capabilities in cutting-edge nuclear medicine technology platforms, international clinical development, and regulatory submissions.</p>\n<p>Leveraging its \"dual submission in China and the U.S.\" strategy for global registration, GRAND PHARMA will continue advancing the worldwide R&D and regulatory efforts for GPN01530. Building on this foundation, the company plans to further deepen its globalization strategy in this sector, actively promoting international clinical research and regulatory filings for more self-developed innovative nuclear medicine products. This initiative aims to enhance GRAND PHARMA's core competitiveness and global influence in nuclear medicine for oncology diagnostics and treatment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1195721045","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195721045","pubTimestamp":1765966230,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GRAND PHARMA (00512) announced that its self-developed global innovative radiopharmaceutical conjugate (RDC) GPN01530 has recently received formal approval from the U.S. Food and Drug Administration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1161":"生物科技","00512":"远大医药","BK1593":"医美概念股","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","01530":"三生制药","BK1583":"高瓴概念"},"translate_title":"远大医药（00512）：自主研发的全球创新放射性药物GPN01530在美国获批临床试验。","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":1,"01530":1},"content_text":"GRAND PHARMA (00512) announced that its self-developed global innovative radiopharmaceutical conjugate (RDC) GPN01530 has recently received formal approval from the U.S. Food and Drug Administration (FDA) to commence Phase I/II clinical studies for the diagnosis of solid tumors. This marks another significant step in the company's global expansion in the field of nuclear medicine for oncology diagnostics and treatment.\nAs the company's first self-developed RDC product to receive FDA approval for clinical trials, the successful clearance of GPN01530's clinical study provides an important model for the international development of GRAND PHARMA's nuclear medicine pipeline. It represents a key milestone in the company's global R&D and regulatory progress for oncology diagnostics and treatment, demonstrating its comprehensive capabilities in cutting-edge nuclear medicine technology platforms, international clinical development, and regulatory submissions.\nLeveraging its \"dual submission in China and the U.S.\" strategy for global registration, GRAND PHARMA will continue advancing the worldwide R&D and regulatory efforts for GPN01530. Building on this foundation, the company plans to further deepen its globalization strategy in this sector, actively promoting international clinical research and regulatory filings for more self-developed innovative nuclear medicine products. This initiative aims to enhance GRAND PHARMA's core competitiveness and global influence in nuclear medicine for oncology diagnostics and treatment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195721045","isCrawlerRequest":true}